AVITA Medical Q2 Revenue Jumps 18% but Going Concern Warning Persists
RCEL sits 68% above its 52-week low of $3.22.
Summary
AVITA Medical reported Q2 2026 revenue of $21.7M (up 18% YoY) and a reduced net loss of $7.7M, but reiterated a going concern warning with only $11.1M in cash and equivalents.
Key Events · Earnings and Guidance · RCEL
-
Q2 Revenue Up 18%
Total revenues reached $21.7 million, driven by RECELL GO and Cohealyx adoption, with gross margin improving to 81.9%.
-
Going Concern Warning Reiterated
Management expressed substantial doubt about the company's ability to continue as a going concern over the next 12 months, citing $11.1 million in cash and equivalents against ongoing losses and debt.
-
Loan Facility Classified as Current
The entire $46.7 million loan facility is classified as a current liability due to the going concern uncertainty, signaling potential acceleration risk.
-
Net Loss Narrows
Net loss improved to $7.7 million from $9.9 million a year ago, helped by revenue growth and a 6% reduction in operating expenses.
Analysis · RCEL · Industrial Applications And Services
AVITA Medical delivered strong Q2 revenue growth of 18% to $21.7 million and narrowed its net loss to $7.7 million from $9.9 million a year ago. However, management reiterated a going concern warning, citing only $11.1 million in cash and equivalents against ongoing losses and debt obligations. The entire $46.7 million loan facility is classified as current, reflecting the risk that the company may not meet its obligations within 12 months without additional funding. While the operational improvements are encouraging, the survival risk dominates the investment thesis.
At the time of this filing, RCEL was trading at $5.41 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $146.2M. The 52-week trading range was $3.22 to $7.12. This filing was assessed with negative market sentiment and an importance score of 9 out of 10.